Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103455
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103455
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103455
Subclassification scheme for adenocarcinomas of the esophagogastric junction and prognostic analysis based on clinicopathological features
Shuo Guo, Li Yuan, Wen-Qian Ma, Li-Mian Er, Department of Endoscopy, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China
Fang-Fang Liu, Department of Nutrition, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China
Qun Zhao, Department of Gastrointestinal Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei Province, China
Author contributions: Guo S and Zhao Q designed the research study; Guo S, Liu FF, Yuan L, Ma WQ, Er LM collected the data; Guo S and Er LM performed the research; Guo S and Liu FF analyzed the data and wrote the manuscript; Zhao Q reviewed the manuscript; All authors have read and approve the final manuscript.
Supported by the Medical Science Research Project of Hebei, No. 20211323.
Institutional review board statement: This study was approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University (Approval No. 2024KY198).
Informed consent statement: This study involves a review of existing medical records and does not require direct interaction with patients. Therefore, it is not possible to obtain informed consent from individual patients. Based on ethical guidelines, a waiver of informed consent has been granted by the Fourth Hospital of Hebei Medical University, as the research poses minimal risk to patient privacy and confidentiality.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qun Zhao, Chief Physician, MD, Department of Gastrointestinal Surgery, Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Changan District, Shijiazhuang 050011, Hebei Province, China. zhaoqun@hebmu.edu.cn
Received: November 21, 2024
Revised: January 11, 2025
Accepted: January 21, 2025
Published online: April 15, 2025
Processing time: 124 Days and 8.2 Hours
Revised: January 11, 2025
Accepted: January 21, 2025
Published online: April 15, 2025
Processing time: 124 Days and 8.2 Hours
Core Tip
Core Tip: This study introduces a novel subclassification for adenocarcinoma of the esophagogastric junction (AEG) based on the tumor center location and esophageal invasion. By distinguishing between types E, Eg, and Ge AEGs, the study identified significant differences in clinicopathological features and prognoses. Type E tumors were associated with poorer outcomes, and the American Joint Committee on Cancer/International Alliance against Cancer gastric cancer staging system more accurately predicted the prognosis of type Ge AEGs than did the esophageal adenocarcinoma system. This subclassification therefore improves prognosis prediction and may guide tailored clinical management for patients with AEG.